{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:40:24Z","timestamp":1793497224324,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"DOI":"10.7759\/cureus.43924","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:43:48Z","timestamp":1692715428000},"source":"Crossref","is-referenced-by-count":12,"title":["Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions"],"prefix":"10.7759","author":[{"given":"Luis A","family":"Bernal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Soti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C","volume":"44","author":"The Global Burden of Hepatitis C Working Group","year":"2004","unstructured":"The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004, 44:20-9. 10.1177\/0091270003258669","journal-title":"J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297922","article-title":"What is killing people with hepatitis C virus infection?","volume":"31","author":"Grebely J","year":"2011","unstructured":"Grebely J, Dore GJ. What is killing people with hepatitis C virus infection?. Semin Liver Dis. 2011, 31:331-9. 10.1055\/s-0031-1297922","journal-title":"Semin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02413","article-title":"Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C","volume":"8","author":"Masavuli MG","year":"2017","unstructured":"Masavuli MG, Wijesundara DK, Torresi J, Gowans EJ, Grubor-Bauk B. Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C. Front Microbiol. 2017, 8:2413. 10.3389\/fmicb.2017.02413","journal-title":"Front Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard T","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997, 349:825-32. 10.1016\/s0140-6736(96)07642-8","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns PB","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011, 128:305-10. 10.1097\/PRS.0b013e318219c171","journal-title":"Plast Reconstr Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a074361","article-title":"Hepatitis","volume":"9","author":"MacCallum FO","year":"1953","unstructured":"MacCallum FO. Hepatitis. Br Med Bull. 1953, 9:221-5. 10.1093\/oxfordjournals.bmb.a074361","journal-title":"Br Med Bull"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104779","article-title":"Inherited antigenic differences in human serum beta lipoproteins. A second antiserum","volume":"42","author":"Blumberg BS","year":"1963","unstructured":"Blumberg BS, Riddell NM. Inherited antigenic differences in human serum beta lipoproteins. A second antiserum. J Clin Invest. 1963, 42:867-75. 10.1172\/JCI104779","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(75)90234-2","article-title":"Clinical and serological analysis of transfusion-associated hepatitis","volume":"2","author":"Alter HJ","year":"1975","unstructured":"Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet. 1975, 2:838-41. 10.1016\/s0140-6736(75)90234-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo QL","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989, 244:359-62. 10.1126\/science.2523562","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.3.983","article-title":"Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis","volume":"87","author":"Miyamura T","year":"1990","unstructured":"Miyamura T, Saito I, Katayama T, et al.. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A. 1990, 87:983-7. 10.1073\/pnas.87.3.983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a072408","article-title":"Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis","volume":"46","author":"Choo QL","year":"1990","unstructured":"Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990, 46:423-41. 10.1093\/oxfordjournals.bmb.a072408","journal-title":"Br Med Bull"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: the clinical spectrum of disease","volume":"26","author":"Hoofnagle JH","year":"1997","unstructured":"Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997, 26:15S-20S. 10.1002\/hep.510260703","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840050406","article-title":"Recombinant leukocyte interferon treatment of chronic hepatitis B","volume":"5","author":"Dusheiko G","year":"1985","unstructured":"Dusheiko G, Dibisceglie A, Bowyer S, Sachs E, Ritchie M, Schoub B, Kew M. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology. 1985, 5:556-60. 10.1002\/hep.1840050406","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle JH","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, et al.. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986, 315:1575-8. 10.1056\/NEJM198612183152503","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(00)80169-5","article-title":"The pattern of response to interferon alpha (\u03b1-IFN) predicts sustained response to a 6-month \u03b1-IFN and ribavirin retreatment for chronic hepatitis C","volume":"33","author":"Cavalletto L","year":"2000","unstructured":"Cavalletto L, Chemello L, Donada C, et al.. The pattern of response to interferon alpha (\u03b1-IFN) predicts sustained response to a 6-month \u03b1-IFN and ribavirin retreatment for chronic hepatitis C. J Hepatol. 2000, 33:128-34. 10.1016\/s0168-8278(00)80169-5","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard O","year":"1991","unstructured":"Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991, 337:1058-61. 10.1016\/0140-6736(91)91707-2","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison JG","year":"1998","unstructured":"McHutchison JG, Gordon SC, Schiff ER, et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1485-92. 10.1056\/NEJM199811193392101","journal-title":"N Engl J Med"},{"key":"ref19","article-title":"Ribavirin in the treatment of hepatitis C","volume":"25","author":"Abonyi ME","year":"2005","unstructured":"Abonyi ME, Lakatos PL. Ribavirin in the treatment of hepatitis C. Anticancer Res. 2005, 25:1315-20.","journal-title":"Anticancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay KL","year":"2001","unstructured":"Lindsay KL, Trepo C, Heintges T, et al.. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001, 34:395-403. 10.1053\/jhep.2001.26371","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1267535","article-title":"New insights into structure and replication of the hepatitis C virus and clinical implications","volume":"30","author":"Poenisch M","year":"2010","unstructured":"Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2010, 30:333-47. 10.1055\/s-0030-1267535","journal-title":"Semin Liver Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2406","article-title":"Hepatitis C virus proteins","volume":"13","author":"Dubuisson J","year":"2007","unstructured":"Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol. 2007, 13:2406-15. 10.3748\/wjg.v13.i17.2406","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson IM","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al.. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011, 364:2405-16. 10.1056\/NEJMoa1012912","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem S","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, et al.. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011, 364:2417-28. 10.1056\/NEJMoa1013086","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad F","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, et al.. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364:1195-206. 10.1056\/NEJMoa1010494","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo P","year":"2010","unstructured":"Kwo P, Lawitz E, McCone J, et al.. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010, 376:705-16. 10.1016\/S0140-6736(10)60934-8","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25448","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy","volume":"91","author":"Poordad F","year":"2019","unstructured":"Poordad F, Bennett M, Sepe TE, et al.. Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy. J Med Virol. 2019, 91:1307-12. 10.1002\/jmv.25448","journal-title":"J Med Virol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32053","article-title":"A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: the PRIORITIZE study","volume":"74","author":"Sulkowski MS","year":"2021","unstructured":"Sulkowski MS, Moon JS, Sherman KE, et al.. A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: the PRIORITIZE study. Hepatology. 2021, 74:2952-64. 10.1002\/hep.32053","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld JJ","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al.. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015, 373:2599-607. 10.1056\/NEJMoa1512610","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.51821\/84.4.015","article-title":"Worldwide prevalence, genotype distribution and management of hepatitis C","volume":"84","author":"Guntipalli P","year":"2021","unstructured":"Guntipalli P, Pakala R, Kumari Gara S, et al.. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021, 84:637-56. 10.51821\/84.4.015","journal-title":"Acta Gastroenterol Belg"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina JP","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015, 61:77-87. 10.1002\/hep.27259","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus JV","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, et al.. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018, 38:181-92. 10.1055\/s-0038-1666841","journal-title":"Semin Liver Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-377","article-title":"Characterization of antigenic variants of hepatitis C virus in immune evasion","volume":"8","author":"Wang JH","year":"2011","unstructured":"Wang JH, Pianko MJ, Ke X, et al.. Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J. 2011, 8:377. 10.1186\/1743-422X-8-377","journal-title":"Virol J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010090","article-title":"Hepatitis C virus vaccine: challenges and prospects","volume":"8","author":"Duncan JD","year":"2020","unstructured":"Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C virus vaccine: challenges and prospects. Vaccines (Basel). 2020, 8:90. 10.3390\/vaccines8010090","journal-title":"Vaccines (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5014-7","article-title":"Cost\/benefit of hepatitis C treatment: it does not end with SVR","volume":"63","author":"Kaplan DE","year":"2018","unstructured":"Kaplan DE. Cost\/benefit of hepatitis C treatment: it does not end with SVR. Dig Dis Sci. 2018, 63:1376-7. 10.1007\/s10620-018-5014-7","journal-title":"Dig Dis Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00864-8","article-title":"Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis","volume":"38","author":"Mattingly TJ 2nd","year":"2020","unstructured":"Mattingly TJ 2nd, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis. Pharmacoeconomics. 2020, 38:233-42. 10.1007\/s40273-019-00864-8","journal-title":"Pharmacoeconomics"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15412","article-title":"Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: a single-arm, open-label, phase 3 trial","volume":"36","author":"Kong F","year":"2021","unstructured":"Kong F, Wen X, Wen X, et al.. Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: a single-arm, open-label, phase 3 trial. J Gastroenterol Hepatol. 2021, 36:2375-82. 10.1111\/jgh.15412","journal-title":"J Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14633","article-title":"Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 trial","volume":"40","author":"Gao Y","year":"2020","unstructured":"Gao Y, Kong F, Li G, et al.. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 trial. Liver Int. 2020, 40:2685-93. 10.1111\/liv.14633","journal-title":"Liver Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i12.1361","article-title":"Daclatasvir plus asunaprevir in treatment-na\u00efve patients with hepatitis C virus genotype 1b infection","volume":"24","author":"Wei L","year":"2018","unstructured":"Wei L, Wang FS, Zhang MX, et al.. Daclatasvir plus asunaprevir in treatment-na\u00efve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol. 2018, 24:1361-72. 10.3748\/wjg.v24.i12.1361","journal-title":"World J Gastroenterol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26652","article-title":"Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir\/velpatasvir for chronic hepatitis C: an open-label study","volume":"93","author":"Chua JV","year":"2021","unstructured":"Chua JV, Ntem-Mensah A, Abutaleb A, et al.. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir\/velpatasvir for chronic hepatitis C: an open-label study. J Med Virol. 2021, 93:3752-60. 10.1002\/jmv.26652","journal-title":"J Med Virol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab334","article-title":"Hepatitis C virus direct-acting antiviral treatment adherence patterns and sustained viral response among people who inject drugs treated in opioid agonist therapy programs","volume":"73","author":"Heo M","year":"2021","unstructured":"Heo M, Pericot-Valverde I, Rennert L, et al.. Hepatitis C virus direct-acting antiviral treatment adherence patterns and sustained viral response among people who inject drugs treated in opioid agonist therapy programs. Clin Infect Dis. 2021, 73:2093-100. 10.1093\/cid\/ciab334","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169306-hepatitis-c-virus-insights-into-its-history-treatment-challenges-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:49Z","timestamp":1707508429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169306-hepatitis-c-virus-insights-into-its-history-treatment-challenges-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.43924","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}